Phil Nadeau

Stock Analyst at TD Cowen

(2.76)
# 1,768
Out of 4,789 analysts
22
Total ratings
47.62%
Success rate
33.34%
Average return

Stocks Rated by Phil Nadeau

Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $6.60
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55$65
Current: $52.97
Upside: +22.71%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300$275
Current: $136.84
Upside: +100.96%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125$120
Current: $70.69
Upside: +69.76%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450$500
Current: $484.82
Upside: +3.13%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $19.68
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $39.07
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.86
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.93
Upside: -
Kezar Life Sciences
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $4.88
Upside: -